Biodistribution of GB-10 (Na(2)(10)B10H10 compound for boron neutron capture therapy (BNCT) in an experimental model of oral cancer in the hamster cheek pouch.
OBJECTIVE
We previously proposed the hamster cheek pouch model of oral cancer for BNCT studies. We herein present the biodistribution of a non-toxic boron compound, GB-10 (Na(2)(10)B10H10), in this model to assess its potential for BNCT or BNCT enhanced Fast Neutron Therapy.


METHODS
We evaluated the uptake and retention of GB-10 in tumour and precancerous tissue and in potentially dose-limiting, clinically relevant normal tissues.


RESULTS
Mean tumour boron concentration delivered by GB-10 (50mgB/kg) peaked to 77.7+/-28.0 ppm at 20min post-administration and remained at therapeutically useful values of 31.9+/-21.4 ppm at 3h. The clearance rate for normal tissues was faster than for tumour tissue. The consistently low brain and spinal cord values would preclude normal tissue toxicity. The uptake of GB-10 by precancerous tissue may be of potential use in the treatment of field cancerized areas. GB-10 was deposited homogeneously in different tumour areas, an asset when treating heterogenous tumours. The data suggests that the joint administration of BPA and GB-10 may improve the therapeutic efficacy of BNCT.


CONCLUSIONS
GB-10 is a potential boron carrier for BNCT of head and neck tumours and for BNCT-FNT.
Heber
Elisa
E
Department of Radiobiology, National Atomic Energy Commission, Avenida del Libertador 8250, 1429 Buenos Aires, Argentina.
Trivillin
Verónica A
VA
Nigg
David
D
Kreimann
Erica L
EL
Itoiz
Maria E
ME
Rebagliati
Raúl J
RJ
Batistoni
Daniel
D
Schwint
Amanda E
AE
D000818:Animals; D001896:Boron Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics*; D016754:Boron Neutron Capture Therapy / Q000379:methods*; D002610:Cheek; D006224:Cricetinae; D004338:Drug Combinations; D004347:Drug Interactions; D023421:Models, Animal; D009062:Mouth Neoplasms / Q000378:metabolism / Q000532:radiotherapy*; D010649:Phenylalanine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D011230:Precancerous Conditions; D011838:Radiation-Sensitizing Agents / Q000493:pharmacokinetics*
C436045:4-dihydroxyborylphenylalanine; D001896:Boron Compounds; D004338:Drug Combinations; D011838:Radiation-Sensitizing Agents; D010649:Phenylalanine